These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21813407)

  • 1. Targeting the right treatments for neuroblastoma.
    Nelson NJ
    J Natl Cancer Inst; 2011 Aug; 103(16):1218-21. PubMed ID: 21813407
    [No Abstract]   [Full Text] [Related]  

  • 2. [Management strategy in neuroblastoma].
    Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():3-8. PubMed ID: 15686038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten challenges in the management of neuroblastoma.
    Gains J; Mandeville H; Cork N; Brock P; Gaze M
    Future Oncol; 2012 Jul; 8(7):839-58. PubMed ID: 22830404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroblastoma: biology, prognosis, and treatment.
    Park JR; Eggert A; Caron H
    Pediatr Clin North Am; 2008 Feb; 55(1):97-120, x. PubMed ID: 18242317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
    Miles SA; Sandler AD
    Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroblastoma. Results of protocol N-I-87].
    Castel Sánchez V; Badal Iranzo MD; Bezanilla Regato JL; Herrero Díez A; Llombart Bosch A; Ruiz Jiménez JI; Sánchez de Toledo J
    An Esp Pediatr; 1993 May; 38(5):471-6. PubMed ID: 8503598
    [No Abstract]   [Full Text] [Related]  

  • 7. New therapeutic targets for the treatment of high-risk neuroblastoma.
    Wagner LM; Danks MK
    J Cell Biochem; 2009 May; 107(1):46-57. PubMed ID: 19277986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Discovery of a gene mutation associated with familial neuroblastoma].
    Nau JY
    Rev Med Suisse; 2008 Sep; 4(169):1888. PubMed ID: 18831412
    [No Abstract]   [Full Text] [Related]  

  • 11. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
    Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
    Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroblastoma: diagnosis and therapy].
    Wargalla-Plate U; Hero B; Berthold F
    Praxis (Bern 1994); 1995 Oct; 84(41):1152-7. PubMed ID: 7481325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    Klin Padiatr; 2005; 217(3):147-52. PubMed ID: 15858706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging and treatment of neuroblastoma.
    Evans AE
    Cancer; 1980 Apr; 45(7 Suppl):1799-1802. PubMed ID: 7370930
    [No Abstract]   [Full Text] [Related]  

  • 15. Personalized medicine. Pushing the envelope in neuroblastoma therapy.
    Couzin-Frankel J
    Science; 2011 Sep; 333(6049):1569-71. PubMed ID: 21921174
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.
    Hutchinson RJ; Sisson JC; Miser JS; Zasadny KR; Normolle DP; Shulkin BL; Francis IR; Wieland DM; Shapiro B
    J Nucl Biol Med (1991); 1991; 35(4):237-40. PubMed ID: 1823826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry.
    Gigliotti AR; Di Cataldo A; Sorrentino S; Parodi S; Rizzo A; Buffa P; Granata C; Sementa AR; Fagnani AM; Provenzi M; Prete A; D'Ippolito C; Clerico A; Castellano A; Tonini GP; Conte M; Garaventa A; De Bernardi B
    Eur J Cancer; 2009 Dec; 45(18):3220-7. PubMed ID: 19767197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
    Caruso DA; Orme LM; Amor GM; Neale AM; Radcliff FJ; Downie P; Tang ML; Ashley DM
    Cancer; 2005 Mar; 103(6):1280-91. PubMed ID: 15693021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
    Simon T; Berthold F; Borkhardt A; Kremens B; De Carolis B; Hero B
    Pediatr Blood Cancer; 2011 Apr; 56(4):578-83. PubMed ID: 21298742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.